hERG-mediated sudden death as a side effect of non-antiarrhythmic drugs has been receiving increased regulatory attention. Perhaps owing to the unique shape of the ligand-binding site and its hydrophobic character, the hERG channel has been shown to interact with pharmaceuticals of widely varying structure. Several in silico approaches have attempted to predict hERG channel blockade. Some of these approaches are aimed primarily at filtering out potential hERG blockers in the context of virtual libraries, others involve understanding structure-activity relationships governing hERG-drug interactions. This review summarizes the most recent efforts in this emerging field.
引用
收藏
页码:149 / 155
页数:7
相关论文
共 43 条
[41]
Towbin JA, 2001, DRUG METAB DISPOS, V29, P574
机构:
Pfizer Ltd, Global Res & Dev, Ion Channel Pharmacol Grp, Sandwich CT13 9NJ, Kent, EnglandPfizer Ltd, Global Res & Dev, Ion Channel Pharmacol Grp, Sandwich CT13 9NJ, Kent, England
Wood, C
Williams, C
论文数: 0引用数: 0
h-index: 0
机构:Pfizer Ltd, Global Res & Dev, Ion Channel Pharmacol Grp, Sandwich CT13 9NJ, Kent, England
Williams, C
Waldron, GJ
论文数: 0引用数: 0
h-index: 0
机构:Pfizer Ltd, Global Res & Dev, Ion Channel Pharmacol Grp, Sandwich CT13 9NJ, Kent, England
机构:
Pfizer Ltd, Global Res & Dev, Ion Channel Pharmacol Grp, Sandwich CT13 9NJ, Kent, EnglandPfizer Ltd, Global Res & Dev, Ion Channel Pharmacol Grp, Sandwich CT13 9NJ, Kent, England
Wood, C
Williams, C
论文数: 0引用数: 0
h-index: 0
机构:Pfizer Ltd, Global Res & Dev, Ion Channel Pharmacol Grp, Sandwich CT13 9NJ, Kent, England
Williams, C
Waldron, GJ
论文数: 0引用数: 0
h-index: 0
机构:Pfizer Ltd, Global Res & Dev, Ion Channel Pharmacol Grp, Sandwich CT13 9NJ, Kent, England